



Common Drug Review *

Submission Status

Product: Ciprodex
Generic Name: ciprofloxacin hydrochloride & dexamethasone otic suspension
Manufacturer: Alcon Canada Inc.
Submission Type: Request for Advice
Date Submission Received: 2007-Jun-15 **Date NOC Issued:** 2004-May-10
Targeted CEDAC Meeting: 2007-Oct-17 **Priority Review Granted:** Not Requested

Phase	Target Time (Business Days)	Target Date**	Actual CDR Date	Comments
1	10	2007-Jun-29	2007-Jun-21	ACP Request for Advice
2	45	2007-Aug-27	2007-Jul-12	Documentation sent to manufacturer. No manufacturer comments required.
3	7			
4	7			
5	5	2007-Oct-02	2007-Jul-13	
6		2007-Sep-19	2007-Sep-19	Request for Advice discussed at July 18, 2007 CEDAC meeting. Response to Request for Advice Pending. Response to Request for Advice placed on September 19, 2007 CEDAC meeting agenda.
7	5	2007-Sep-26	2007-Sep-26	An embargoed CEDAC recommendation issued in response to this Request for Advice.
8 (a)	10	2007-Oct-11	2007-Oct-11	
OR				
8 (b)				
9 (a)	5	2007-Oct-18	2007-Oct-18	Notice of Final Recommendation issued.
OR				
9 (b)	5			
OR				
9 (c)	25 Depends on Meeting Dates			
10	5			

* Refer to the Procedure for Common Drug Review on the Common Drug Review section of www.cadth.ca for more details.

** The CDR review process is initiated AFTER submission is assessed. The target dates for this report are based on the CEDAC meeting schedule, which is posted on www.cadth.ca

*** The Recommendation and Reasons for Recommendation are to be held in confidence and not acted upon until after the CDR Directorate has issued the notice of Final Recommendation.

Reflects updates as of Thursday noon.